急性髓系白血病长期生存者的生活质量和生活满意度
该横断面问卷研究纳入427例确诊后≥5年(中位11.3年)的急性髓系白血病长期生存者,总体生活质量与生活满意度汇总评分高于年龄/性别匹配的参照队列(p<0.001),但差异小且可能无临床意义;27%报告生活质量受损,13%报告总体生活满意度受损,17%报告健康相关生活满意度受损。
要点
- AML长期生存者总体生活质量与生活满意度评分高于匹配参照队列(p<0.001),但差异小可能无临床意义。
- 27%的生存者报告生活质量受损,13%报告总体生活满意度受损,17%报告健康相关生活满意度受损。
- 异基因造血干细胞移植未对生活质量、总体生活满意度或健康相关生活满意度产生不良影响。
核心结论
- AML长期生存者的总体生活质量和生活满意度与一般人群相当,且与治疗方式无关,但部分生存者报告总体生活质量或特定领域存在有临床意义的受损。
- 研究识别了与结局受损相关的因素(如合并症和疲乏),界定出AML诊断后≥5年仍有未满足需求的生存者亚组。
研究设计与样本
- 基于问卷的横断面研究,分析急性髓系白血病长期生存者的结局,包括心理社会健康和躯体健康状况。
- 共427例既往AML患者参与(应答率63%),距白血病诊断≥5年且至多18.6年(中位11.3年)。
- 参与研究时中位年龄61岁(范围28岁-93岁),23%曾经历疾病复发,63%接受过异基因造血干细胞移植(alloHSCT)。
主要发现
- AML长期生存者的生活质量(QoL)和总体生活满意度(gLS)汇总评分高于年龄/性别匹配的参照队列(p < 0.001),但差异小且可能无临床意义。
- 报告生活质量受损的生存者占27%,报告总体生活满意度受损的占13%,报告健康相关生活满意度(hrLS)受损的占17%。
- 采用多变量回归模型识别了上述各项结局的易感因素和保护因素。
- 接受异基因造血干细胞移植治疗未对生活质量、总体生活满意度或健康相关生活满意度产生不良影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We performed a questionnaire-based cross-sectional study to analyze Acute Myeloid Leukemia (AML) long-term survivor (LTS) outcomes, including psychosocial well-being and somatic health status. Four-hundred-twenty-seven former AML patients participated (response rate, 63%) ≥5 years[y] and up to 18.6 y past their leukemia diagnosis (median, 11.3 y). Median age at study participation was 61 y (range 28y-93y), 23% had experienced disease relapse, and 63% had received allogeneic hematopoietic stem cell transplantation (alloHSCT). Overall, quality of life (QoL) and general life satisfaction (gLS) summary scores were higher in AML LTS (p < 0.001) compared to age-/sex-matched reference cohorts, although differences were small and likely not clinically relevant. However, we identified subgroups of survivors reporting impaired QoL (27%), gLS (13%) and health-related life satisfaction (hrLS; 17%). Using multivariable regression models, we identified predisposing and protective factors for each of these outcomes. Treatment with alloHSCT did not adversely impact QoL, gLS, or hrLS. In summary, global QoL and LS in AML LTS are comparable to the general population, irrespective of treatment modality, although some survivors report clinically significant impairment of global QoL and/or in specific domains. We identified factors associated with impaired outcomes (e.g., comorbidity and fatigue), delineating a subgroup of survivors with unmet needs ≥5 y after their AML diagnosis.
引用
- Telzerow E, Görlich D, Sauerland C, et al. Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia. Leukemia. 2025. PMID: 40847197. doi:10.1038/s41375-025-02735-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。